HERON THERAPEUTICS, INC. /DE/ Cash Flow Statement
HRTX|2 years of annual SEC 10-K data (FY2016-FY2017)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
HERON THERAPEUTICS, INC. /DE/ used $79M in operating cash flow and negative free cash flow of $80M in FY2017.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 | FY2016 |
|---|---|---|
| Net Income | -$97.6M | -$76.4M |
| Depreciation & Amortization | $734.0K | $578.0K |
| Operating Cash Flow | -$78.5M | -$60.3M |
| Capital Expenditures | $1.1M | $1.4M |
| Free Cash Flow | -$79.6M | -$61.7M |
| FCF Margin | -6224.6% | -4825.7% |